<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511418550</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511418550</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing–remitting multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Calabrese</surname><given-names>Massimiliano</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511418550">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Federle</surname><given-names>Lisa</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511418550">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bernardi</surname><given-names>Valentina</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511418550">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rinaldi</surname><given-names>Francesca</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511418550">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Favaretto</surname><given-names>Alice</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511418550">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Varagnolo</surname><given-names>Maria Cristina</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511418550">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Perini</surname><given-names>Paola</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511418550">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Plebani</surname><given-names>Mario</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511418550">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gallo</surname><given-names>Paolo</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511418550">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511418550"><label>1</label>Multiple Sclerosis Centre, Department of Neuroscience, University Hospital of Padova, Italy.</aff>
<aff id="aff2-1352458511418550"><label>2</label>Chemical Chemistry Laboratory, University Hospital of Padova, Italy.</aff>
<author-notes>
<corresp id="corresp1-1352458511418550">Dr Massimiliano Calabrese, Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Via Giustiniani 5, 35128 Padova, Italy Email: <email>calabresem@hotmail.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>2</issue>
<fpage>174</fpage>
<lpage>180</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>2</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>6</day>
<month>7</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>8</day>
<month>7</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> The intrathecal production of immunoglobulin (Ig) is a major biological feature of multiple sclerosis (MS), and immunopathological studies have suggested a primary role of the humoral immune response in causing irreversible brain damage.</p>
<p><bold>Objective:</bold> To evaluate whether, in the early phases of MS, intrathecal Ig synthesis correlates with the presence of cortical lesions (CLs), and if their association could predict the clinical course of the disease.</p>
<p><bold>Methods:</bold> Eighty-six patients presenting with symptoms and signs suggestive of MS underwent a diagnostic work-up that included magnetic resonance imaging and cerebrospinal fluid examination. The risk ratios (RR) for conversion to MS and for a new disease activity were calculated.</p>
<p><bold>Results:</bold> Patients with clinically isolated syndromes (CIS) having CLs and intrathecal synthesis of Ig had the highest risk of conversion to MS (RR = 3.4; Wald 95% CI = 1.7–7.0, <italic>p</italic> &lt; 0.001) whereas CIS patients without CLs and intrathecal synthesis of Ig had the lowest risk of conversion to MS (RR = 0.1, Wald 95% CI = 0.02–0.7, <italic>p</italic> &lt; 0.001). The highest risk of having disease-related activity during the follow-up was observed in CIS and relapsing–remitting MS patients showing CLs and intrathecal Ig synthesis (RR = 2.1; Wald 95% CI = 1.5–3.1, <italic>p</italic> &lt; 0.001) while the lowest in CIS and relapsing–remitting MS patients without CLs and intrathecal Ig synthesis (RR = 0.3; Wald 95% CI = 0.1–0.7, <italic>p</italic> &lt; 0.001).</p>
<p><bold>Conclusion:</bold> We observed that the association of intrathecal immunoglobulin synthesis and CLs was highly predictive of an earlier CIS conversion to MS as well as of a higher disease activity.</p>
</abstract>
<kwd-group>
<kwd>cortical lesions</kwd>
<kwd>double-inversion recovery</kwd>
<kwd>intrathecal Ig synthesis</kwd>
<kwd>magnetic resonance imaging</kwd>
<kwd>multiple sclerosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458511418550" sec-type="intro">
<title>Introduction</title>
<p>The early identification of clinically isolated syndromes (CIS) patients having high risk of conversion to multiple sclerosis (MS) and of MS patients who may have a more severe disease evolution may be clinically relevant since an early immunomodulatory therapy can significantly delay the conversion rate<sup><xref ref-type="bibr" rid="bibr1-1352458511418550">1</xref>,<xref ref-type="bibr" rid="bibr2-1352458511418550">2</xref></sup> and the disease progression.</p>
<p>Although several magnetic resonance imaging (MRI) parameters have been proved to be useful diagnostic and prognostic markers in CIS and relapsing remitting Multiple Sclerosis (RRMS),<sup><xref ref-type="bibr" rid="bibr3-1352458511418550">3</xref>–<xref ref-type="bibr" rid="bibr7-1352458511418550">7</xref></sup> the demonstration of intrathecally synthesized IgG still constitutes a diagnostic aid in MS,<sup><xref ref-type="bibr" rid="bibr8-1352458511418550">8</xref>–<xref ref-type="bibr" rid="bibr10-1352458511418550">10</xref></sup> and the presence of anti-myelin lipid IgM antibodies and an increase in B-1 cells in the cerebro-spinal fluid (CSF) have been associated to a more aggressive disease course.<sup><xref ref-type="bibr" rid="bibr11-1352458511418550">11</xref>–<xref ref-type="bibr" rid="bibr14-1352458511418550">14</xref></sup> All these observations stimulate further investigation on the clinical use of intrathecally synthesized Ig in MS.</p>
<p>Recent neuropathological<sup><xref ref-type="bibr" rid="bibr15-1352458511418550">15</xref>,<xref ref-type="bibr" rid="bibr16-1352458511418550">16</xref></sup> and neuroimaging<sup><xref ref-type="bibr" rid="bibr17-1352458511418550">17</xref>,<xref ref-type="bibr" rid="bibr18-1352458511418550">18</xref></sup> studies have demonstrated that cortical lesions (CLs) are a relevant phenomenon in MS brain. Albeit more frequent in secondary progressive MS, CLs can be observed since the early MS stages,<sup><xref ref-type="bibr" rid="bibr18-1352458511418550">18</xref>,<xref ref-type="bibr" rid="bibr19-1352458511418550">19</xref></sup> may significantly improve the specificity of the currently used diagnostic criteria<sup><xref ref-type="bibr" rid="bibr20-1352458511418550">20</xref></sup> and have a high prognostic value given their association with physical and cognitive disability.<sup><xref ref-type="bibr" rid="bibr21-1352458511418550">21</xref>,<xref ref-type="bibr" rid="bibr22-1352458511418550">22</xref></sup> Moreover, their presence has been found associated with the presence of oligoclonal IgG bands (IgGOB) in the CSF.<sup><xref ref-type="bibr" rid="bibr18-1352458511418550">18</xref></sup></p>
<p>Given these premises, we have investigated, in CIS and early untreated RRMS patients, the relationship between the global intrathecal humoral immune response (IgG and IgM) and the presence of CLs, and evaluated if their combination could be applied for diagnostic and prognostic purposes.</p>
</sec>
<sec id="section2-1352458511418550" sec-type="methods">
<title>Methods</title>
<sec id="section3-1352458511418550">
<title>Patients</title>
<p>From 1 July 2006 to 30 June 2007, 94 consecutive patients presenting with symptoms and signs suggestive of an inflammatory CNS disease, underwent a detailed diagnostic work-up, including CSF examination and MRI with Double Inversion Recovery (DIR) sequences, that disclosed a non-MS-related pathology in eight patients. The remaining 86 (see Results section and <xref ref-type="table" rid="table1-1352458511418550">Table 1</xref>) were included in a three year longitudinal study during which they underwent EDSS<sup><xref ref-type="bibr" rid="bibr23-1352458511418550">23</xref></sup> evaluation every year and in case of a relapse (each patient was clinically evaluated by a single neurologist), and MRI monitoring as foreseen by the McDonald/Polman’s international guidelines<sup><xref ref-type="bibr" rid="bibr24-1352458511418550">24</xref>,<xref ref-type="bibr" rid="bibr25-1352458511418550">25</xref></sup> for demonstration of dissemination in space and time of lesions, and then every year. The mean interval of time between the first and the last MRI examination was 36 months (standard deviation ±3 months, range: 31–40 months).</p>
<table-wrap id="table1-1352458511418550" position="float">
<label>Table 1.</label>
<caption>
<p>Demographic, clinical, CSF and MRI parameters of all the patients included in the study</p>
</caption>
<graphic alternate-form-of="table1-1352458511418550" xlink:href="10.1177_1352458511418550-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">CIS/DIS−, <italic>n</italic> = 19</th>
<th align="left">CIS/DIS+, <italic>n</italic> = 27</th>
<th align="left">eRRMS, <italic>n</italic> = 40</th>
<th align="left">Whole group, <italic>n</italic> = 86</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male (ratio)</td>
<td>12/7 (1.7)</td>
<td>18/9 (2.0)</td>
<td>26/14 (1.8)</td>
<td>56/30 (1.9)</td>
</tr>
<tr>
<td>Age (years)<xref ref-type="table-fn" rid="table-fn1-1352458511418550">*</xref></td>
<td>30.4 ± 5.1 (19–45)</td>
<td>31.3 ± 6.2 (18–42)</td>
<td>33.5 ± 6.1 (18–50)</td>
<td>32.1 ± 6.1 (18–50)</td>
</tr>
<tr>
<td>Disease duration (years)<xref ref-type="table-fn" rid="table-fn1-1352458511418550">*</xref></td>
<td>0.1 ± 0.3 (0–0.5)</td>
<td>0.1 ± 0.3 (0–0.4)</td>
<td>1.2 ± 0.5 (0.5–2)</td>
<td>0.6 ± 0.5 (0–2)</td>
</tr>
<tr>
<td>EDSS<xref ref-type="table-fn" rid="table-fn1-1352458511418550">*</xref></td>
<td>1.0 ± 0.9 (0–3.0)</td>
<td>1.8 ± 1.2 (1.0–3.5)</td>
<td>2.0 ± 1.1 (1.0–3.0)</td>
<td>1.71 ± 1.2 (0–3.5)</td>
</tr>
<tr>
<td>T2-WMLV (cm<sup>3</sup>)<xref ref-type="table-fn" rid="table-fn1-1352458511418550">*</xref></td>
<td>1.1 ± 2.2 (0.2–3.8)</td>
<td>4.6 ± 4.8 (0.4–10.2)</td>
<td>5.2 ± 5.1 (0.5–12.3)</td>
<td>4.1 ± 5.1 (0.4–12.3)</td>
</tr>
<tr>
<td>CL number<xref ref-type="table-fn" rid="table-fn1-1352458511418550">*</xref></td>
<td>0.9 ± 2.3 (0–13)</td>
<td>3.9 ± 3.0 (0–14)</td>
<td>4.3 ± 3.2 (0–14)</td>
<td>3.4 ± 3.3 (0–14)</td>
</tr>
<tr>
<td>CL+ patients (%)</td>
<td>4 (21.0)</td>
<td>21 (77.8)</td>
<td>26 (65.0)</td>
<td>51 (59.3)</td>
</tr>
<tr>
<td>IgM<sub>(loc)</sub>+ (%)</td>
<td>1 (5.3)</td>
<td>10 (37.0)</td>
<td>12 (30.0)</td>
<td>23 (26.7)</td>
</tr>
<tr>
<td>IgG Index ≥ 0.7 (%)</td>
<td>4 (21.0)</td>
<td>16 (59.3)</td>
<td>28 (70.0)</td>
<td>48 (55.8)</td>
</tr>
<tr>
<td>IgGOB+ (%)</td>
<td>2 (10.5)</td>
<td>21 (77.8)</td>
<td>35 (87.5)</td>
<td>58 (67.4)</td>
</tr>
<tr>
<td>Ig+ (%)</td>
<td>6 (31.5)</td>
<td>23 (85.2)</td>
<td>38 (95.0)</td>
<td>67 (77.9)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458511418550">
<label>*</label>
<p>For these parameters the mean ± SD and range (into brackets) are reported.</p>
</fn>
<fn id="table-fn2-1352458511418550">
<p>CIS: Clinically isolated syndrome suggestive of MS, DIS: dissemination in space of the lesions, eRRMS: early relapsing remitting MS, EDSS: Expanded Disability Status Scale, T2-WMLV: T2 white matter lesion volume, CLs: cortical lesions, IgM<sub>(loc)</sub>+: intrathecal IgM synthesis, IgGOB+: intrathecal synthesis of IgG oligoclonal bands.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>At follow-up, patients were considered clinically worsened if they had an increase of at least one point in a functional system of EDSS. Three neurologists (M.C., P.P. and P.G.) with great experience in MS have evaluated the patients and Expanded Disability Status Scale (EDSS) changes were always confirmed, by the same neurologist, in a second visit performed after three months. A patient having no relapse, no 3-month sustained change in EDSS score, and no evidence of new MRI activity (T1 gad+ or active T2 lesions), over the follow-up period, was considered ‘disease-free’.<sup><xref ref-type="bibr" rid="bibr26-1352458511418550">26</xref></sup> The study was approved by the local Ethics Commitee and informed consent was obtained from all patients.</p>
</sec>
<sec id="section4-1352458511418550">
<title>Examination of cerebro-spinal fluid</title>
<p>After informed consent had been obtained, paired CSF and peripheral blood samples were collected between 8.00 and 9.00 a.m. Standard CSF parameters (glucose, proteins, cell count, Alb CSF/serum ratio, and IgG index) were routinely assessed. IgGOB were detected by means of isoelectric focusing followed by immunoblotting for IgG. IgM were quantified by immunonephelometry in CSF and serum; the IgM hyperbolic function (IgM<sub>(loc)</sub> = [Q(IgM) − <italic><sup>a</sup></italic>/<italic><sub>b</sub></italic>√Q(Alb)<sup>2 </sup>+ <italic>b</italic><sup>2 </sup>+ <italic>c</italic>]) was applied to identify patients with intrathecal IgM synthesis (IgM<sub>(loc)</sub>+).<sup><xref ref-type="bibr" rid="bibr5-1352458511418550">5</xref></sup> For statistical purposes the intrathecal IgM synthesis was interpreted with reference to the Qmean + 2SD (standard deviations) as upper limit of the reference range for blood-derived proteins in CSF.<sup><xref ref-type="bibr" rid="bibr27-1352458511418550">27</xref>,<xref ref-type="bibr" rid="bibr28-1352458511418550">28</xref></sup> Patients with an intrathecal synthesis of Ig (i.e. IgM and/or IgG) were named Ig+ patients.</p>
</sec>
<sec id="section5-1352458511418550">
<title>Image acquisition</title>
<p>All images were acquired using a 1.5 T scanner (Achieva; Philips Medical Systems, Best, Netherlands) with a power gradient of 33 mT/m, and a 16-channel head coil. No major hardware upgrades of the scanner occurred during the study period. The following images were acquired from each subject at baseline and at the time-points above described : (1) DIR: repetition time (TR) = 15,631 ms, echo time (TE) = 25 ms, inversion time (TI) = 3400 ms, delay = 325 ms, echo train length (ETL) = 17, fifty contiguous axial slices with a thickness = 3 mm, matrix size = 130 × 256, field of view (FOV) = 250 × 200 mm;(2) fast fluid attenuated inversion recovery (FLAIR): TR = 10,000 ms, TE = 120 ms, TI = 2500 ms, ETL = 23, fifty contiguous axial slices with a thickness = 3.0 mm, matrix size = 172 × 288, FOV = 250 × 200 mm.</p>
</sec>
<sec id="section6-1352458511418550">
<title>Image analysis</title>
<p>All images were assessed by consensus by two experienced observers, who were blinded to patient identity. At baseline the number of CLs was assessed on DIR images following the recent recommendations for CLs scoring in patients with MS.<sup><xref ref-type="bibr" rid="bibr28-1352458511418550">28</xref></sup> The appearance of artefacts on DIR sequence has been carefully evaluated on the base of the images obtained from large number of patients and healthy control subjects, as described elsewhere.<sup><xref ref-type="bibr" rid="bibr15-1352458511418550">15</xref></sup></p>
<p>On FLAIR images, the T2-white matter lesion volume (T2-WMLV) was quantified, after lesion identification, using a semi-automated local thresholding technique based on Fuzzy C-mean algorithm part of the Medical Images Processing, Analysis and Visualization (MIPAV) software (<ext-link ext-link-type="uri" xlink:href="http://mipav.cit.nih.gov">http://mipav.cit.nih.gov</ext-link>).</p>
</sec>
<sec id="section7-1352458511418550">
<title>Statistical analysis</title>
<p>Between-group differences were assessed using the analysis of variance (ANOVA). The Pearson χ<sup>2</sup> was applied to test the association between biological (presence/absence of intrathecal IgG or IgM synthesis and presence of IgGOB) and MRI (presence/absence of CLs and of dissemination in space of WM lesions) markers at baseline, and to test the association between biological and MRI markers, and clinical [i.e. number of new relapses, number of clinically worsened patients (i.e. patients with an increase in EDSS of at least one point in a functional system)] and radiological (new T2 WM lesions, new CL, disease-free status) outcomes at follow-up.</p>
<p>Sensitivity and specificity of the biological and MRI markers were assessed using clinical or radiological conversion (only in the CIS group) and a new disease activity (new clinical relapse, new WM lesion, new CL) as outcome. The risks of conversion to MS and new disease activity were assessed using the risk ratio (RR). Differences in time to new disease activity were evaluated using the Kaplan–Meier survival curves.</p>
<p>A stepwise linear regression analysis was performed to assess the relative contributions of baseline variables (EDSS, T2-WMLV, CL number, IgGOB, IgG index, IgM<sub>(loc)</sub>+, Ig+) in predicting clinical or radiological disease activity at follow-up. Forward and backward stepwise analyses were corrected for age and were conducted (using the Wald statistic as a criterion), with a <italic>p</italic>-value for entry of 0.05, and a <italic>p</italic>-value for removal of 0.1. All statistical analyses were performed using SPSS v.18 and R, a statistical package available at <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link>.</p>
</sec>
</sec>
<sec id="section8-1352458511418550" sec-type="results">
<title>Results</title>
<sec id="section9-1352458511418550">
<title>Baseline data</title>
<sec id="section10-1352458511418550">
<title>Clinical classification of patients</title>
<p>At baseline, according to the international diagnostic criteria<sup><xref ref-type="bibr" rid="bibr24-1352458511418550">24</xref>,<xref ref-type="bibr" rid="bibr25-1352458511418550">25</xref></sup> the patients were classified as follows: (1) clinically isolated syndrome without dissemination in space of the lesions (CIS/DIS−; <italic>n</italic> = 19), when presenting with the first clinical episode suggestive of inflammatory demyelination, but missing the criteria for dissemination in space of the lesions; (2) clinically isolated syndrome with dissemination in space of the lesions (CIS/DIS+; <italic>n</italic> = 27), when presenting with the first clinical episode having evidence of dissemination in space, but not in time, of the lesions; and (3) early relapsing–remitting MS (eRRMS; <italic>n</italic> = 40): patients with at least two clinical episodes in which the evidence of dissemination in time of lesions was therefore clinically achieved. Clinical, CSF, MRI and demographic characteristics of the patients are summarized in <xref ref-type="table" rid="table1-1352458511418550">Table 1</xref>.</p>
</sec>
<sec id="section11-1352458511418550">
<title>Intrathecal immunoglobulin synthesis</title>
<p>Twenty-three (26.7%) patients were found to have an intrathecal synthesis of IgM (IgM<sub>(loc)</sub>+). Forty-eight (55.8%) patients had an increased IgG index (mean value = 0.76 ± 0.43; range: 0.38–2.88). IgGOB were demonstrated in 58/86 (67.4%) patients (<xref ref-type="table" rid="table1-1352458511418550">Table 1</xref>). An intrathecal synthesis of Ig (Ig+ patients) was therefore detected in 67/86 (77.9%) patients.</p>
</sec>
<sec id="section12-1352458511418550">
<title>T2 lesion load and intrathecal Ig synthesis</title>
<p>T2-WMLV was significantly higher in IgGOB+ patients (5.2 ± 4.3, range: 0.9–12.3) compared with patients without IgGOB (1.8 ± 2.2, range: 0.4–7.1; <italic>p</italic> &lt; 0.001) and in patients with increased IgG Index (4.9 ± 3.7, range: 0.8–12.3) compared to patients with normal IgG index (3.1 ± 3.2, range: 0.4–5.4, <italic>p</italic> = 0.002). Also IgM<sub>(loc)</sub>+ patients had higher T2-WMLV (4.3 ± 3.0, range: 0.4–12.3) compared with IgM<sub>(loc)</sub>− patients (4.0 ± 3.0, range: 0.5–11.2), but the difference did not reach statistical significance (<italic>p</italic> = 0.115). Ig+ patients had higher T2-WMLV (4.2 ± 3.6, range: 0.4–12.3) compared with Ig− patients (3.7 ± 3.3, range: 0.5–11.2, <italic>p</italic> = 0.021).</p>
</sec>
<sec id="section13-1352458511418550">
<title>Cortical lesions and intrathecal Ig synthesis</title>
<p>CLs could be detected in 51/86 (59.3%) patients among which 4/19 (21.0%) were CIS/DIS−, 21/27 (77.8%) were CIS/DIS+ and 26/40 (65.0%) were eRRMS, see Table 1.</p>
<p>The mean number of CLs was 3.4 ± 3.3 (range: 0–14) in the whole group, but it was higher (<italic>p</italic> &lt; 0.001) in IgM<sub>(loc)</sub>+ patients (7.2 ± 4.5, range: 0–14) than in IgM<sub>(loc)</sub>− (2.0 ± 2.5, range: 0–6), in patients with increased IgG index (5.6 ± 4.1; range: 0–14) compared with patients with normal IgG index (0.6 ± 1.1; range: 0–4; <italic>p</italic> &lt; 0.001) and in patients having IgGOB (4.8 ± 3.8; range: 0–13) compared with patients without IgGOB (0.5 ± 1.0; range: 0–3; <italic>p</italic> &lt; 0.001).</p>
</sec>
</sec>
<sec id="section14-1352458511418550">
<title>Follow-up data</title>
<sec id="section15-1352458511418550">
<title>Prognostic factors of conversion to multiple sclerosis</title>
<p>During the 3-year follow-up, among the 46 patients at their first clinical episode (CIS), 25 (five CIS/DIS−, 20 CIS/DIS+) converted to definite MS according to the McDonald/Polman Criteria<sup><xref ref-type="bibr" rid="bibr24-1352458511418550">24</xref>,<xref ref-type="bibr" rid="bibr25-1352458511418550">25</xref></sup> (see <xref ref-type="table" rid="table2-1352458511418550">Table 2</xref>): 13 patients (two CIS/DIS−, 11 CIS/DIS+) experienced a new clinical relapse, 15 (three CIS/DIS−, 12 CIS/DIS+) had the appearance of new T2 WM lesion and 13 (two CIS/DIS− and 11 CIS/DIS+) showed a new CL on MRI. Eleven out of 25 (44%) had an increased EDSS score at the end of the follow-up. All 25 patients started an immunomodulatory therapy (nine glatiramer acetate and 16 interferon beta) at the time of conversion.</p>
<table-wrap id="table2-1352458511418550" position="float">
<label>Table 2.</label>
<caption>
<p>Number (percentage) of CIS patients with clinical or MRI events during the 3-year follow-up</p>
</caption>
<graphic alternate-form-of="table2-1352458511418550" xlink:href="10.1177_1352458511418550-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">New relapse</th>
<th align="left">Increased EDSS</th>
<th align="left">New T2 lesion</th>
<th align="left">New CLs</th>
<th align="left">Converted to MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>All CIS (<italic>n</italic> = 46)</td>
<td>13 (28.2%)</td>
<td>11 (23.9%)</td>
<td>15 (32.6%)</td>
<td>13 (28.2%)</td>
<td>25 (54.4%)</td>
</tr>
<tr>
<td>DIS+ (pMS; <italic>n</italic> = 27)</td>
<td>11 (40.7%)</td>
<td>10 (37.0%)</td>
<td>12 (44.4%)</td>
<td>11 (40.7%)</td>
<td>20 (74.0%)</td>
</tr>
<tr>
<td>CLs+ (<italic>n</italic> = 25)</td>
<td>8 (32.0%)</td>
<td>6 (24.0%)</td>
<td>9 (36.0%)</td>
<td>8 (32%)</td>
<td>19 (76.0%)</td>
</tr>
<tr>
<td>IgM<sub>(loc)</sub> + (<italic>n</italic> = 11)</td>
<td>7 (63.6%)</td>
<td>4 (36.4%)</td>
<td>8 (72.7%)</td>
<td>7 (63.6%)</td>
<td>9 (81.8%)</td>
</tr>
<tr>
<td>IgG index ≥ 0.7 (<italic>n</italic> = 20)</td>
<td>8 (40.0%)</td>
<td>5 (25%)</td>
<td>11 (55.0%)</td>
<td>9 (45.0%)</td>
<td>12 (60.0%)</td>
</tr>
<tr>
<td>IgGOB+ (<italic>n</italic> = 23)</td>
<td>12 (52.8%)</td>
<td>7 (30.4%)</td>
<td>14 (60.8%)</td>
<td>12 (52.8%)</td>
<td>17 (73.9%)</td>
</tr>
<tr>
<td>Ig+ and CLs+ (<italic>n</italic> = 22)</td>
<td>12 (54.5%)</td>
<td>8 (36.4%)</td>
<td>12 (54.5%)</td>
<td>14 (63.6%)</td>
<td>19 (86.4%)</td>
</tr>
<tr>
<td>Ig− and CLs− (<italic>n</italic> = 13)</td>
<td>1 (7.7%)</td>
<td>1 (7.7%)</td>
<td>0</td>
<td>0</td>
<td>1 (7.7%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458511418550">
<p>DIS: dissemination in space of the lesions, CL: cortical lesion, IgM<sub>(loc)</sub>+: intrathecal IgM synthesis, Ig, intrathecally synthesized Ig.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Ig+/CLs+ patients had the highest probability to convert to MS in the following 3 years (RR = 3.4; Wald 95% CI = 1.7–7.0. <italic>p</italic> &lt; 0.001; see <xref ref-type="table" rid="table2-1352458511418550">Table 2</xref> and <xref ref-type="table" rid="table3-1352458511418550">Table 3</xref>). In contrast, Ig−/CL− patients remained disease-free until the end of the follow-up (RR to convert: 0.1, Wald 95% CI = 0.02–0.7, <italic>p</italic> &lt; 0.001). Sensitivity, specificity and RR of these parameters are summarized in <xref ref-type="table" rid="table3-1352458511418550">Table 3</xref>.</p>
<table-wrap id="table3-1352458511418550" position="float">
<label>Table 3.</label>
<caption>
<p>The prognostic values of different biological and MRI parameters at baseline in predicting the conversion to MS in all CIS patients during the 3-year follow-up</p>
</caption>
<graphic alternate-form-of="table3-1352458511418550" xlink:href="10.1177_1352458511418550-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">Sensitivity (%)</th>
<th align="left">Specificity (%)</th>
<th align="left">Accuracy (%)</th>
<th align="left">Risk ratio (Wald 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIS+ (<italic>n</italic> = 27)</td>
<td>80.0</td>
<td>66.7</td>
<td>73.9</td>
<td>2.8 (1.3–6.2)<xref ref-type="table-fn" rid="table-fn4-1352458511418550">*</xref></td>
</tr>
<tr>
<td>IgM<sub>(loc)</sub>+ (<italic>n</italic> = 11)</td>
<td>36.0</td>
<td>90.5</td>
<td>60.9</td>
<td>1.8 (1.1–2.8)<xref ref-type="table-fn" rid="table-fn4-1352458511418550">*</xref></td>
</tr>
<tr>
<td>CL+ (25)</td>
<td>76.0</td>
<td>71.4</td>
<td>73.9</td>
<td>2.7 (1.3–5.4)<xref ref-type="table-fn" rid="table-fn4-1352458511418550">*</xref></td>
</tr>
<tr>
<td>IgG index ≥ 0.7 (<italic>n</italic> = 20)</td>
<td>48.0</td>
<td>61.9</td>
<td>54.3</td>
<td>1.2 (0.7–2.0)</td>
</tr>
<tr>
<td>IgGOB+ (<italic>n</italic> = 23)</td>
<td>68.0</td>
<td>71.4</td>
<td>69.6</td>
<td>2.1 (1.2–3.9)<xref ref-type="table-fn" rid="table-fn4-1352458511418550">*</xref></td>
</tr>
<tr>
<td>Ig+ and CL+ (<italic>n</italic> = 22)</td>
<td>76.0</td>
<td>85.7</td>
<td>80.4</td>
<td>3.4 (1.7–7.0)<xref ref-type="table-fn" rid="table-fn4-1352458511418550">**</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1352458511418550">
<p>Pearson’s <italic>χ</italic><sup>2</sup> *<italic>p</italic>-value &lt; 0.05; **<italic>p</italic>-value &lt; 0.001.</p>
</fn>
<fn id="table-fn5-1352458511418550">
<p>DIS: dissemination in space of the lesions according to the international diagnostic criteria,<sup><xref ref-type="bibr" rid="bibr2-1352458511418550">2</xref>,<xref ref-type="bibr" rid="bibr3-1352458511418550">3</xref></sup> CL: cortical lesion, IgM<sub>(loc)</sub>+: intrathecal IgM synthesis, Ig: intrathecally synthesized Ig.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section16-1352458511418550">
<title>Prognostic factors of disease activity</title>
<p>Twenty-seven out of the 86 patients included in the study, had a new clinical relapse, 23 of these increased their EDSS of at least 1 point and were considered clinically worsened, 38 showed a new T2 WM lesion and 38 a new CL while 27/86 (31.4%) remained disease free.</p>
<p>All the patients (including eRRMS) were therefore clustered according to the presence of intrathecally synthesized Ig (Ig+ and Ig−) and the presence of CLs (CL+ and CL−) at study entry, thus identifying four groups of patients (<xref ref-type="table" rid="table4-1352458511418550">Table 4</xref>). The group Ig+/CL+ had the worse clinical and/or MRI evolution (<xref ref-type="fig" rid="fig1-1352458511418550">Figure 1</xref>). Indeed, this association was highly predictive of disease activity in the following 3 years (RR = 2.1; Wald 95%CI = 1.5–3.1; <italic>p</italic> &lt; 0.001; see <xref ref-type="table" rid="table5-1352458511418550">Table 5</xref>) whereas Ig−/CL− patients had the lowest risk of a new disease-related event during follow-up (RR = 0.3; Wald 95% CI = 0.1–0.7, <italic>p</italic> &lt; 0.001).The risk of a new disease-related event (clinical or MRI) was also evaluated in patients having evidence of dissemination in space of the lesions, in patients with an intrathecal IgM synthesis and in patients with an intrathecal IgGOB synthesis of (see <xref ref-type="table" rid="table5-1352458511418550">Table 5</xref> for more details).</p>
<table-wrap id="table4-1352458511418550" position="float">
<label>Table 4.</label>
<caption>
<p>Number of patients with clinical or MRI events during the 3-year follow-up period</p>
</caption>
<graphic alternate-form-of="table4-1352458511418550" xlink:href="10.1177_1352458511418550-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2" valign="bottom">Parameter</th>
<th align="left" colspan="2">Ig−, <italic>n</italic> = 19</th>
<th align="left" colspan="2">Ig+, <italic>n</italic> = 67</th>
<th align="left" rowspan="2" valign="bottom">DIS+, <italic>n</italic> = 54</th>
</tr>
<tr>
<th align="left">CL−, <italic>n</italic> = 16</th>
<th align="left">CL+, <italic>n</italic> = 3</th>
<th align="left">CL−, <italic>n</italic> = 23</th>
<th align="left">CL+, <italic>n</italic> = 44</th>
</tr>
</thead>
<tbody>
<tr>
<td>New relapse</td>
<td>1 (6.2%)</td>
<td>1 (33.3%)</td>
<td>4 (17.4%)</td>
<td>21 (47.7%)<xref ref-type="table-fn" rid="table-fn6-1352458511418550">*</xref></td>
<td>22 (40.7%)</td>
</tr>
<tr>
<td>Increased EDSS</td>
<td>1 (6.2%)</td>
<td>3 (100%)</td>
<td>2 (8.7%)</td>
<td>17 (38.6%)<xref ref-type="table-fn" rid="table-fn6-1352458511418550">*</xref></td>
<td>17 (31.5%)</td>
</tr>
<tr>
<td>New T2 lesion</td>
<td>1 (6.2%)</td>
<td>3 (100%)</td>
<td>4 (17.4%)</td>
<td>30 (54.5%)<xref ref-type="table-fn" rid="table-fn6-1352458511418550">*</xref></td>
<td>33 (61.1%)</td>
</tr>
<tr>
<td>New CL</td>
<td>4 (25.0%)</td>
<td>2 (66.7%)</td>
<td>6 (26.0%)</td>
<td>26 (68.2%)<xref ref-type="table-fn" rid="table-fn6-1352458511418550">*</xref></td>
<td>30 (55.6%)</td>
</tr>
<tr>
<td>Disease-free status</td>
<td>12 (75.0%)</td>
<td>1 (33.3%)</td>
<td>11 (47.8%)</td>
<td>3 (6.8%)<xref ref-type="table-fn" rid="table-fn6-1352458511418550">*</xref></td>
<td>17 (31.5%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1352458511418550">
<label>*</label>
<p><italic>p</italic>-value &lt;0.001 compared to all the other patients.</p>
</fn>
<fn id="table-fn7-1352458511418550">
<p>DIS: dissemination in space of the lesions according to the international diagnostic criteria,<sup><xref ref-type="bibr" rid="bibr2-1352458511418550">2</xref>,<xref ref-type="bibr" rid="bibr3-1352458511418550">3</xref></sup> CL: cortical lesion, Ig: intrathecally synthesized Ig.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1352458511418550" position="float">
<label>Figure 1.</label>
<caption>
<p>Kaplan–Meier estimates for the probability of disease activity (new clinical relapse and/or new T2 lesions at MRI) at 3years.</p>
</caption>
<graphic xlink:href="10.1177_1352458511418550-fig1.tif"/>
</fig>
<table-wrap id="table5-1352458511418550" position="float">
<label>Table 5.</label>
<caption>
<p>The prognostic values of different biological and MRI parameters at baseline in predicting a new clinical or MRI disease activity during the 3-year follow-up in the whole group</p>
</caption>
<graphic alternate-form-of="table5-1352458511418550" xlink:href="10.1177_1352458511418550-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="left">Sensitivity (%)</th>
<th align="left">Specificity (%)</th>
<th align="left">Accuracy (%)</th>
<th align="left">Risk ratio (Wald 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIS+ (<italic>n</italic> = 54)</td>
<td>72.9</td>
<td>59.3</td>
<td>68.6</td>
<td>1.6 (1.1–2.3)<xref ref-type="table-fn" rid="table-fn8-1352458511418550">*</xref></td>
</tr>
<tr>
<td>IgM<sub>(loc)</sub>+ (<italic>n</italic> = 23)</td>
<td>35.6</td>
<td>92.6</td>
<td>53.5</td>
<td>1.5 (1.2–1.9)<xref ref-type="table-fn" rid="table-fn8-1352458511418550">*</xref></td>
</tr>
<tr>
<td>CL+ (<italic>n</italic> = 51)</td>
<td>69.5</td>
<td>63.0</td>
<td>67.4</td>
<td>1.6 (1.1–2.2)<xref ref-type="table-fn" rid="table-fn8-1352458511418550">*</xref></td>
</tr>
<tr>
<td>IgGOB+ (<italic>n</italic> = 58)</td>
<td>76.3</td>
<td>51.9</td>
<td>68.6</td>
<td>1.5 (1.0–2.3)<xref ref-type="table-fn" rid="table-fn8-1352458511418550">*</xref></td>
</tr>
<tr>
<td>Ig+ and CL+</td>
<td>69.5</td>
<td>88.9</td>
<td>75.6</td>
<td>2.1 (1.5–3.1)<xref ref-type="table-fn" rid="table-fn8-1352458511418550">**</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-1352458511418550">
<p>Pearson’s <italic>χ</italic><sup>2</sup> *<italic>p</italic>-value &lt; 0.05; **<italic>p</italic>-value &lt; 0.001.</p>
</fn>
<fn id="table-fn9-1352458511418550">
<p>DIS: dissemination in space of the lesions according to the international diagnostic criteria,<sup>2,3</sup> CL: cortical lesion, IgM<sub>(loc)</sub>+: intrathecal IgM synthesis, Ig: intrathecally synthesized Ig.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section17-1352458511418550">
<title>Multivariate analysis</title>
<p>In the entire patient population both the forward and backward stepwise regression showed that baseline CL number (<italic>B</italic> = 0.51, <italic>p</italic> &lt; 0.001) and the intrathecal synthesis of Ig (<italic>B</italic> = 0.54, <italic>p</italic> &lt; 0.001) were independent predictors of disease activity at 3 years.The final model including these variables showed an <italic>r</italic><sup>2 </sup>= 0.64, adjusted <italic>r</italic><sup>2 </sup>= 0.62, <italic>F</italic> = 33 903, <italic>p</italic> &lt; 0.001.</p>
</sec>
</sec>
</sec>
<sec id="section18-1352458511418550" sec-type="discussion">
<title>Discussion</title>
<p>The rationale for studying the relationship between CLs and intrathecally synthesized Ig is based on the following observations. Ig and B cells are frequently observed in MS lesions;<sup><xref ref-type="bibr" rid="bibr29-1352458511418550">29</xref>,<xref ref-type="bibr" rid="bibr30-1352458511418550">30</xref></sup> autoantibodies can be locally synthesized by a T-independent B lymphocytes<sup><xref ref-type="bibr" rid="bibr31-1352458511418550">31</xref></sup> that have been found to be increased in MS CSF and to correlate with intrathecal IgM production;<sup><xref ref-type="bibr" rid="bibr32-1352458511418550">32</xref></sup> cortical demyelination may be associated with subpial ectopic B-cell follicle-like structures<sup><xref ref-type="bibr" rid="bibr33-1352458511418550">33</xref>,<xref ref-type="bibr" rid="bibr34-1352458511418550">34</xref></sup> and the presence of IgGOB in the CSF correlates with CLs more than with WM lesions.<sup><xref ref-type="bibr" rid="bibr18-1352458511418550">18</xref></sup></p>
<p>On the base of this rationale, we tested the combination of intrathecal Ig production with CLs showing that it was strongly predictive of disease activity, evaluated according with the most recent published definition,<sup><xref ref-type="bibr" rid="bibr26-1352458511418550">26</xref></sup> in the subsequent 3 years. Such result extends the previous observation on the association between CLs and intrathecally synthesized IgGOB.<sup><xref ref-type="bibr" rid="bibr18-1352458511418550">18</xref></sup> This combination identified a subgroup of CIS Ig+/CL+ patients having a higher risk of developing definite MS in the following 3 years compared to Ig−/CL− patients (that have the highest probability to be disease free after 3 years), as well as to patients with a disseminations in space of white matter lesions (i.e. DIS+). Moreover, it identified the eRRMS having the highest risk of disease activity during the follow-up.</p>
<p>Although the present study has several limitations (i.e. single centre, low number of CIS, limitation of DIR in detecting CLs),<sup><xref ref-type="bibr" rid="bibr18-1352458511418550">18</xref>,<xref ref-type="bibr" rid="bibr35-1352458511418550">35</xref></sup> our findings come from a relatively large population of consecutive patients followed for at least 3 years by a specialized MS team and therefore can be considered a first evidence of the possible diagnostic and prognostic value of the association between CLs and intrathecal Ig production in CIS and eRRMS, respectively. Of course, further attempts aimed at confirming the value of such association should be performed.</p>
<p>In summary, in our longitudinal study we observed that (1) the intrathecal synthesis of Ig (IgG and IgM) was strongly associated with CLs at early MS stages; (2) the association Ig+/CL+ was highly predictive of the subsequent disease activity and, thus, marked a subgroup of patients having a worse clinical evolution; (3) this association may help to develop diagnostic criteria that enable an earlier diagnosis of MS; and (4) Ig−/CL− patients may constitute a relatively benign MS group. Finally, our findings may allow a better selection of MS patients for early and more aggressive disease-modifying therapies.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This work was supported by grants from the University of Padova (Project N. CPDA 099394) and the Italian Ministry of Public Health (Istituto Superiore di Sanità, Project N. 3 Biomarkers and Diagnosis, ISS 17).</p>
</fn>
<fn fn-type="conflict">
<p>The authors report no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511418550">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Freedman</surname><given-names>MS</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<etal/>
</person-group>. <article-title>Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study</article-title>. <source>Lancet</source> <year>2007</year>; <volume>370</volume>: <fpage>389</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511418550">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clerico</surname><given-names>M</given-names></name>
<name><surname>Faggiano</surname><given-names>F</given-names></name>
<name><surname>Palace</surname><given-names>J</given-names></name>
<name><surname>Rice</surname><given-names>G</given-names></name>
<name><surname>Tintorè</surname><given-names>M</given-names></name>
<name><surname>Durelli</surname><given-names>L</given-names></name>
</person-group>. <article-title>Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis</article-title>. <source>Cochrane Database Syst Rev</source> <year>2008</year>; <month>April</month> <volume>16</volume>(<issue>2</issue>): <fpage>CD005278</fpage>.</citation>
</ref>
<ref id="bibr3-1352458511418550">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Riordan</surname><given-names>JI</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
<name><surname>Kingsley</surname><given-names>DP</given-names></name>
<etal/>
</person-group>. <article-title>The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up</article-title>. <source>Brain</source> <year>1998</year>; <volume>121</volume>(<issue>Pt 3</issue>): <fpage>495</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511418550">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brex</surname><given-names>PA</given-names></name>
<name><surname>Ciccarelli</surname><given-names>O</given-names></name>
<name><surname>O’Riordan</surname><given-names>JI</given-names></name>
<name><surname>Sailer</surname><given-names>M</given-names></name>
<name><surname>Thompson</surname><given-names>AJ</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
</person-group>. <article-title>A longitudinal study of abnormalities on MRI and disability from multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2002</year>; <volume>346</volume>: <fpage>158</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511418550">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>C</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Freedman</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b</article-title>. <source>J Neurology</source> <year>2008</year>; <volume>255</volume>: <fpage>480</fpage>–<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511418550">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lebrun</surname><given-names>C</given-names></name>
<name><surname>Bensa</surname><given-names>C</given-names></name>
<name><surname>Debouverie</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients</article-title>. <source>Arch Neurol</source> <year>2009</year>; <comment>l</comment>; <volume>66</volume>: <fpage>841</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511418550">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Swanton</surname><given-names>JK</given-names></name>
<name><surname>Fernando</surname><given-names>KT</given-names></name>
<name><surname>Dalton</surname><given-names>CM</given-names></name>
<etal/>
</person-group>. <article-title>Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>156</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511418550">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tintorè</surname><given-names>M</given-names></name>
<name><surname>Rovira</surname><given-names>A</given-names></name>
<name><surname>Rio</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?</article-title> <source>Neurology</source> <year>2008</year>; <volume>70</volume>(<issue>13, Pt 2</issue>): <fpage>1079</fpage>–<lpage>1083</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511418550">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Awad</surname><given-names>A</given-names></name>
<name><surname>Hemmer</surname><given-names>B</given-names></name>
<name><surname>Hartung</surname><given-names>HP</given-names></name>
<name><surname>Kieseier</surname><given-names>B</given-names></name>
<name><surname>Bennett</surname><given-names>JL</given-names></name>
<name><surname>Stuve</surname><given-names>O</given-names></name>
</person-group>. <article-title>Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis</article-title>. <source>J Neuroimmunol</source> <year>2010</year>; <volume>219</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511418550">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rojas</surname><given-names>JI</given-names></name>
<name><surname>Patrucco</surname><given-names>L</given-names></name>
<name><surname>Cristiano</surname><given-names>E</given-names></name>
</person-group>. <article-title>Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis</article-title>. <source>J Neurol</source> <year>2010</year>; <volume>257</volume>: <fpage>1188</fpage>–<lpage>1191</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511418550">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>Masjuan</surname><given-names>J</given-names></name>
<name><surname>González-Porqué</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS</article-title>. <source>Neurology</source> <year>2002</year>; <volume>59</volume>: <fpage>555</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511418550">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>Masjuan</surname><given-names>J</given-names></name>
<name><surname>González-Porqué</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2003</year>; <volume>53</volume>: <fpage>222</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511418550">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>Sádaba</surname><given-names>MC</given-names></name>
<name><surname>Roldán</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS</article-title>. <source>J Clin Invest</source> <year>2005</year>; <volume>115</volume>: <fpage>187</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr14-1352458511418550">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perini</surname><given-names>P</given-names></name>
<name><surname>Ranzato</surname><given-names>F</given-names></name>
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Battistin</surname><given-names>L</given-names></name>
<name><surname>Gallo</surname><given-names>P</given-names></name>
</person-group>. <article-title>Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2006</year>; <volume>77</volume>: <fpage>953</fpage>–<lpage>955</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511418550">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kidd</surname><given-names>D</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>McConnell</surname><given-names>R</given-names></name>
<name><surname>Algra</surname><given-names>PR</given-names></name>
<name><surname>Allen</surname><given-names>IV</given-names></name>
<name><surname>Revesz</surname><given-names>T</given-names></name>
</person-group>. <article-title>Cortical lesions in multiple sclerosis</article-title>. <source>Brain</source> <year>1999</year>; <volume>122</volume>(<issue>Pt 1</issue>): <fpage>17</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511418550">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peterson</surname><given-names>JW</given-names></name>
<name><surname>Bö</surname><given-names>L</given-names></name>
<name><surname>Mörk</surname><given-names>S</given-names></name>
<name><surname>Chang</surname><given-names>A</given-names></name>
<name><surname>Trapp</surname><given-names>BD</given-names></name>
</person-group>. <article-title>Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions</article-title>. <source>Ann Neurol</source> <year>2001</year>; <volume>50</volume>: <fpage>389</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511418550">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>Pouwels</surname><given-names>PJ</given-names></name>
<name><surname>Uitdehaag</surname><given-names>BM</given-names></name>
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Castelijns</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion–recovery MR imaging</article-title>. <source>Radiology</source> <year>2005</year>; <volume>236</volume>: <fpage>254</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511418550">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>De Stefano</surname><given-names>N</given-names></name>
<name><surname>Atzori</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2007</year>; <volume>64</volume>: <fpage>1416</fpage>–<lpage>1422</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511418550">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Atzori</surname><given-names>M</given-names></name>
<name><surname>Bernardi</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Cortical atrophy is relevant in multiple sclerosis at clinical onset</article-title>. <source>JNeurol</source> <year>2007</year>; <volume>254</volume>: <fpage>1212</fpage>–<lpage>1220</lpage>.</citation>
</ref>
<ref id="bibr20-1352458511418550">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filippi</surname><given-names>M</given-names></name>
<name><surname>Rocca</surname><given-names>MA</given-names></name>
<name><surname>Calabrese</surname><given-names>M</given-names></name>
</person-group>. <article-title>Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis</article-title>. <source>Neurology</source> <year>2010</year>; <volume>75</volume>: <fpage>1988</fpage>–<lpage>1994</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511418550">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Rocca</surname><given-names>MA</given-names></name>
<name><surname>Atzori</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>376</fpage>–<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511418550">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Agosta</surname><given-names>F</given-names></name>
<name><surname>Rinaldi</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Cortical lesions and atrophy associated with cognitive impairment in relapsing–remitting multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>1144</fpage>–<lpage>1150</lpage>.</citation>
</ref>
<ref id="bibr23-1352458511418550">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title>. <source>Neurology</source> <year>1983</year>; <volume>33</volume>: <fpage>1444</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr24-1352458511418550">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>WI</given-names></name>
<name><surname>Compston</surname><given-names>A</given-names></name>
<name><surname>Edan</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2001</year>; <volume>50</volume>: <fpage>121</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr25-1352458511418550">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Edan</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”</article-title>. <source>Ann Neurol</source> <year>2005</year>; <volume>58</volume>: <fpage>840</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr26-1352458511418550">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giovannoni</surname><given-names>G</given-names></name>
<name><surname>Cook</surname><given-names>S</given-names></name>
<name><surname>Rammohan</surname><given-names>K</given-names></name>
<name><surname>Rieckmann</surname><given-names>P</given-names></name>
</person-group>. <article-title>Sustained disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis</article-title>. <source>Lancet Neurol</source> <year>2011</year>; <volume>10</volume>: <fpage>329</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511418550">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiber</surname><given-names>H</given-names></name>
<name><surname>Peter</surname><given-names>JB</given-names></name>
</person-group>. <article-title>Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs</article-title>. <source>J Neurol Sci</source> <year>2001</year>; <volume>184</volume>: <fpage>101</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511418550">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiber</surname><given-names>H</given-names></name>
<name><surname>Albaum</surname><given-names>W</given-names></name>
</person-group>. <article-title>Statistical evaluation of intrathecal protein synthesis in CSF/Serum quotient diagrams</article-title>. <source>Acta Neuropsychiatrica</source> <year>2008</year>; <volume>20</volume>: <fpage>48</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511418550">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mead</surname><given-names>RJ</given-names></name>
<name><surname>Singhrao</surname><given-names>SK</given-names></name>
<name><surname>Neal</surname><given-names>JW</given-names></name>
<name><surname>Lassmann</surname><given-names>H</given-names></name>
<name><surname>Morgan</surname><given-names>BP</given-names></name>
</person-group>. <article-title>The membrane attack complex of complement causes severe demyelination associated with acute axonal injury</article-title>. <source>J Immunol</source> <year>2002</year>; <volume>168</volume>: <fpage>458</fpage>–<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511418550">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>W</given-names></name>
<name><surname>Lucchinetti</surname><given-names>CF</given-names></name>
</person-group>. <article-title>The pathological spectrum of CNS inflammatory demyelinating diseases</article-title>. <source>Semin Immunopathol</source> <year>2009</year>; <volume>31</volume>: <fpage>439</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr31-1352458511418550">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berland</surname><given-names>R</given-names></name>
<name><surname>Wortis</surname><given-names>HH</given-names></name>
</person-group>. <article-title>Origins and functions of B-1 cells with notes on the role of CD5</article-title>. <source>Annu Rev Immunol</source> <year>2002</year>; <volume>20</volume>: <fpage>253</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr32-1352458511418550">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villar</surname><given-names>LM</given-names></name>
<name><surname>Espiño</surname><given-names>M</given-names></name>
<name><surname>Cavanillas</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. <article-title>Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis</article-title>. <source>Clin Immunol</source> <year>2010</year>; <volume>137</volume>: <fpage>51</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr33-1352458511418550">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magliozzi</surname><given-names>R</given-names></name>
<name><surname>Howell</surname><given-names>O</given-names></name>
<name><surname>Vora</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology</article-title>. <source>Brain</source> <year>2007</year>; <volume>130</volume>(<issue>Pt 4</issue>): <fpage>1089</fpage>–<lpage>1104</lpage>.</citation>
</ref>
<ref id="bibr34-1352458511418550">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Serafini</surname><given-names>B</given-names></name>
<name><surname>Rosicarelli</surname><given-names>B</given-names></name>
<name><surname>Magliozzi</surname><given-names>R</given-names></name>
<name><surname>Stigliano</surname><given-names>E</given-names></name>
<name><surname>Aloisi</surname><given-names>F</given-names></name>
</person-group>. <article-title>Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis</article-title>. <source>Brain Pathol</source> <year>2004</year>; <volume>14</volume>: <fpage>164</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr35-1352458511418550">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>Roosendaal</surname><given-names>SD</given-names></name>
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>418</fpage>–<lpage>424</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>